Valuation: NewAmsterdam Pharma Company N.V.

Market Cap 3.24B 3.7B 2.99B 2.75B 5.19B 357B 5.3B 35.7B 14.04B 175B 13.91B 13.6B 601B P/E 2026 *
-17.7x
P/E 2027 * -20.8x
Enterprise Value 2.83B 3.24B 2.62B 2.41B 4.54B 312B 4.65B 31.26B 12.3B 153B 12.18B 11.91B 527B EV / Sales 2026 *
121x
EV / Sales 2027 * 20.3x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -
1 week-9.87%
Current month-6.81%
1 month+6.38%
3 months-5.92%
6 months+1.69%
Current year-5.92%
1 week 26.51
Extreme 26.51
30.48
1 month 25.56
Extreme 25.56
32.38
3 years 5.45
Extreme 5.45
35.6
Manager TitleAgeSince
Chief Executive Officer 69 2022-10-31
Director of Finance/CFO 52 2023-10-22
Chief Operating Officer 53 2021-02-28
Director TitleAgeSince
Director/Board Member 77 2022-10-31
Director/Board Member 63 2025-04-14
Director/Board Member 64 2022-10-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-9.87%+54.53%+163.43% 3.7B
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.77%-2.62%+41.94%+181.98% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.78%+143.44%

Financials

2026 *2027 *
Net sales 23.43M 26.82M 21.62M 19.93M 37.57M 2.58B 38.4M 258M 102M 1.26B 101M 98.5M 4.35B 133M 152M 123M 113M 213M 14.65B 218M 1.47B 577M 7.18B 571M 559M 24.71B
Net income -191M -218M -176M -162M -306M -21.04B -313M -2.11B -828M -10.3B -820M -802M -35.47B -168M -192M -155M -143M -269M -18.5B -275M -1.85B -728M -9.06B -721M -705M -31.18B
Net Debt -402M -460M -371M -342M -644M -44.29B -659M -4.43B -1.74B -21.69B -1.73B -1.69B -74.67B -538M -616M -497M -458M -863M -59.31B -882M -5.94B -2.33B -29.05B -2.31B -2.26B -99.99B
Logo NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Employees
-
Date Price Change
26-07-17 €27.66 +1.84%
26-07-16 €27.16 -3.17%
26-07-15 €28.05 -3.44%
26-07-14 €29.05 -0.58%
26-07-13 €29.22 -4.79%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.69EUR
Average target price
43.58EUR
Spread / Average Target
+57.41%

Quarterly revenue - Rate of surprise